Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 819

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 819
---
, and (b) that is designed and intended to be of a size and statistical power sufficient to serve as a pivotal study to support the filing of an MAA for the Indication being studied.

1.59 “Pre-ClinicalCandidate” means a Licensed ADC Directed to SEZ6
or MUC16 [***].

1.60 “Pricing and Reimbursement Approval” means, with respect to any Region in the
Territory in which governmental authorities determine the pricing at which a Licensed Product will be reimbursed, the approval, agreement, determination or decision by the applicable governmental authorities establishing the pricing and
reimbursement status for such Licensed Product.

1.61 “Prior CDA” means that certain Mutual Confidentiality
Agreement, dated [***], between WuXi Biologics (Hong Kong) Limited, Hangzhou DAC Biotechnology Co., Ltd. and Aadi [***], as may be amended by the parties thereto from time to time.

1.62 “Program” means (a) the MUC16 Program, (b) the PTK7 Program or (c) the SEZ6 Program.

1.63 “Program Patent” means any Patent claiming an Invention.

1.64 “PTK7 Program” means WuXi Biologics’ pre-clinical development
program relating to PTK7, as licensed to and further Exploited by Aadi hereunder.

1.65 “Region” means a
jurisdiction (a country or region) in the Territory.

1.66 “Regulatory Approval” means all approvals,
licenses, registrations or authorizations of any governmental entity that are necessary for the manufacturing, use, storage, import, transport and sale of Licensed ADCs or Licensed Products in a regulatory jurisdiction, including in each case,
Pricing and Reimbursement Approval.

1.67 “Regulatory Authority” means any national (e.g., the FDA) or,
supra-national (e.g., the EMA), or other governmental entity in any jurisdiction of the world involved in the granting of Regulatory Approval for pharmaceutical products.

1.68 “Regulatory Filing” means all approvals, licenses, registrations, submissions and authorizations made to or
received from a Regulatory Authority in a jurisdiction necessary for or in connection with the development, manufacture and/or commercialization of a pharmaceutical product, including any INDs, Marketing Approval Applications and Regulatory
Approvals.

1.69 “Segregate” means, with respect to a Competing Product, to use